Genmab A/SGMAB
Price (close)
$34.83
Market cap
—
P/E
—
Revenue (FY)
$3.7B
Net income
$963.0M
Dividend yield
—
1-year total return
20.8%
Net margin
25.9%
Revenue growth
19.2%
Debt / equity
0.86x
What Genmab A/S does.
diseases. Our goal in building our pipeline is to bring medicines to market ourselves in geographic areas where we believe
for the treatment of thyroid eye disease (“ TED ”). In addition BIZENGRI (Z enocutuumab-zbco ) was added to our portfolio
of royalty medicines as part of our acquisition of Merus. Merus exclusively licensed to Partner Therapeutics Inc. (" P artner
Revenue and profit, by fiscal year.
| Fiscal year | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.4B | $3.1B | $3.7B |
| Net income | — | — | — | $631.0M | $1.1B | $963.0M |
| Free cash flow | — | — | — | $1.0B | $1.1B | $1.1B |
More on GMAB.
- Genmab A/S summary
- Genmab A/S financial statements
- Genmab A/S key metrics
- Genmab A/S health scores and style box
- Genmab A/S earnings
- Genmab A/S dividends
- Genmab A/S valuation
- Genmab A/S ownership and insiders
- Genmab A/S peers
Figures from Genmab A/S's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.